ChemoMetec Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Martin Behrens

Chief Executive Officer (CEO)

DKK 2.9m

Compensación total

Porcentaje del salario del CEO	30.0%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Martin Behrens en comparación con los beneficios de ChemoMetec?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	DKK 3m	DKK 877k	DKK 136m

Compensación vs. Mercado: La compensación total de Martin($USD412.53K) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD1.45M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Martin con los resultados de la empresa.

CEO

Martin Behrens (32 yo)

less than a year

Permanencia

DKK 2,923,041

Compensación

Mr. Martin Helbo Behrens serves as CEO at ChemoMetec A/S since March 13, 2024. He is Chief Operating Officer of ChemoMetec A/S from December 2023. He was Vice Chief Operating Officer of ChemoMetec A/S from...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Behrens	CEO & COO	less than a year	DKK 2.92m	sin datos
Hans Glensbjerg	Deputy Chairman & Senior Advisor	no data	DKK 150.00k	0.31% DKK 24.3m
Kim Nicolajsen	Chief Financial Officer	less than a year	sin datos	sin datos
Christopher Runchel	Chief Sales Officer	no data	sin datos	sin datos
Marta Planaguma	Chief Marketing & Strategy Officer	less than a year	sin datos	sin datos
Lisbet Helles	Head of Marketing	less than a year	sin datos	sin datos
Søren Kjærulff	Head of R&D	no data	sin datos	sin datos
Bo Nielsen	Chief R&D Officer and Physicist & Project Manager	less than a year	sin datos	sin datos

0.9yrs

Permanencia media

44yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CHEMMC no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hans Glensbjerg	Deputy Chairman & Senior Advisor	no data	DKK 150.00k	0.31% DKK 24.3m
Peter Reich	Independent Director	10.1yrs	DKK 100.00k	0.0083% DKK 649.1k
Kristine Faerch	Independent Director	4.1yrs	DKK 100.00k	0.00032% DKK 24.9k
Niels Thestrup	Chairman	3.1yrs	DKK 360.00k	0.011% DKK 872.8k
Betina Hagerup	Independent Director	3.1yrs	DKK 100.00k	0.0017% DKK 130.9k

3.6yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de CHEMMC se considera experimentada (3.6 años de antigüedad promedio).

ChemoMetec Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

ChemoMetec A/S Announces CFO Changes

ChemoMetec A/S Announces CEO Changes

ChemoMetec A/S Announces Executive Changes

ChemoMetec A/S Announces Executive Changes

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

Recent updates

ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025

ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA.

ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA.

ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025

ChemoMetec A/S Approves Dividend

ChemoMetec A/S Approves Dividend

ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.

ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.

ChemoMetec A/S provides earnings guidance for the year 2024/25

ChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025

ChemoMetec A/S Announces CFO Changes

ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24

ChemoMetec A/S Announces CEO Changes

Investor sentiment improves as stock rises 30%

ChemoMetec A/S Maintains Earnings Guidance for the Year 2024

ChemoMetec A/S Announces Executive Changes

ChemoMetec A/S Announces Executive Changes

Investor sentiment deteriorates as stock falls 22%

Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022)

Chemometec A/S Proposes Dividend for the 2022/23 Financial Year

New minor risk - Financial data availability

ChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024

ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023

First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)

ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023

Investor sentiment deteriorated over the past week

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)

Less than half of directors are independent

ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023

Less than half of directors are independent

Less than half of directors are independent

ChemoMetec A/S, Annual General Meeting, Oct 12, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Upcoming dividend of kr.4.00 per share

Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020)

Less than half of directors are independent

New 90-day high: kr.620

First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020)

New 90-day high: kr.459

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad